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Cerebral blood ﬂow is mainly regulated by nitrergic (parasympathetic, postganglionic) nerves and nitric
oxide (NO) liberated from endothelial cells in response to shear stress and stretch of vasculature,
whereas sympathetic vasoconstrictor control is quite weak. On the other hand, peripheral vascular
resistance and blood ﬂow are mainly controlled by adrenergic vasoconstrictor nerves; endothelium-
derived NO and nitrergic nerves play some roles as vasodilator factors. Cigarette smoking impairs NO
synthesis in cerebral vascular endothelial cells and nitrergic nerves leading to interference with cerebral
blood ﬂow and glucose metabolism in the brain. Smoking-induced cerebral hypoperfusion is induced by
impairment of synthesis and actions of NO via endothelial nitric oxide synthase (eNOS)/neuronal NOS
(nNOS) inhibition and by increased production of oxygen radicals, resulting in decreased actions of NO
on vascular smooth muscle. Nicotine acutely and chronically impairs the action of endothelial NO and
also inhibits nitrergic nerve function in chronic use. Impaired cerebral blood supply promotes the syn-
thesis of amyloid b that accelerates blood ﬂow decrease. This vicious cycle is thought to be one of the
important factors involving in Alzheimer's disease (AD). Quitting smoking is undoubtedly one of the
important ways to prevent and delay the genesis or slow the progress of impaired cognitive function and
AD.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
The epoch-making discovery of endothelium-derived relaxing
factor by Furchgott and Zawadzki (1) led to the seminal ﬁnding that
this factor is the gaseous molecule nitric oxide (NO) liberated from
endothelial cells via stimulation by chemical substances such as
acetylcholine (ACh), ATP, bradykinin and substance P or application
of physical stimuli like shear stress and stretch to endothelial cells
(2). Cerebral blood ﬂow increase is mainly mediated via
endothelium-derived NO and NO liberated from nitrergic nerves
innervating vasculatures (3). Parasympathetic postganglionic
(nitrergic) nerves play quite important roles in dilating the cerebral
vasculature, but the counteracting vasoconstrictor actions ofardiovascular Pharmacology
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d/4.0/).adrenergic nerves is only minimal in the brain. In contrast, in extra-
cerebral vasculatures, adrenergically-induced vasoconstriction is
more evident than nitrergic nerve-derived vasodilatation (4).
Therefore, cerebral arterial tone and blood ﬂow are mainly regu-
lated by endothelium- and nitrergic nerve-derived NO.
Impaired blood supply to the brain owing to cerebral vascular
dysfunction is a major clinical feature of Alzheimer's disease (AD)
(5). One of the important factors inducing cerebral hypoperfusion is
impairment of actions of NO derived from endothelia and nitrergic
nerves on vascular smoothmuscle (6). Therefore, reduced synthesis
and actions of constitutively synthesized NO result in decreased
blood ﬂow and reduced glucose supply to the brain, possibly
leading to impaired cognitive function and AD. Decreased blood
supply to the brain induces both increased amyloid b (Ab) pro-
duction (7) and decreased clearance of intraneuronal Ab (8) and Ab
inhibits endothelial function; this vicious cycle is expected to play a
role in deteriorating brain function (9). Vasodilator actions of NO
are impaired by the production of oxygen radicals and the synthesis
of NO is blocked by an endogenously liberated NOS inhibitor,
asymmetric dimethyl-arginine (ADMA), which is formed fromnese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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Therefore, these factors are expected to reduce the actions of NO
from the endothelia and neurons, thus decreasing blood ﬂow to the
brain. Cigarette smoking is known to reduce cerebral blood ﬂow
due to interfering with endothelial function and to degradation of
NO by producing oxygen radicals (11) (Fig. 1).
This review summarizes the possible mechanisms of action of
active and passive smoking or nicotine on cerebral vascular endo-
thelial function, nitrergic nerve function and blood ﬂow in refer-
ence to cognitive failure and AD. Recent advances in the
prophylaxis and drug therapies against AD are summarized with
special emphasis. Smoking is internationally accepted to be one of
the important factors promoting impairment of cerebral blood
perfusion and generation of cognitive failure and AD.
2. Smoking and cerebral vascular tone and blood ﬂow
In the brain, blood ﬂow is regulated not only by pial arterioles
but also by the main trunk of the basal cerebral arteries; there-
fore, arterial and arteriolar diameter changes are important fac-
tors inﬂuencing cerebral blood ﬂow (12). The oxidative stress
induced by cigarette smoke exposure is a potential mechanism
for initiating cardiovascular dysfunction, including impairment of
endothelial function and NO-mediated vasodilatation (13). Infu-
sion of aqueous cigarette smoke extract into the alveolar air space
of an isolated lung mounted in tyrosine solution increased so-
dium peroxynitrite and 3-nitrotyrosine, suggesting that relatively
stable oxidants in the smoke extract appear to pass through the
pulmonary alveolar wall into the blood and induce systemic
oxidative stress, which likely facilitates oxidative modiﬁcation of
low-density lipoprotein and endothelial dysfunction (14). Rat
cerebral arterioles (closed cranial preparations) were dilated by
topical application of ACh. One hour after a one-minute exposure
to cigarette smoke, ACh constricted the cerebral arterioles, butFig. 1. Schematic presentation of NO synthesis and its degradation and also sites of action
nerve; eNOS, endothelial NOS; nNOS, neuronal NOS; L-Arg, L-arginine; L-Citru, L-citrulline; A
O2, superoxide anion; sGCred, reduced soluble guanylyl cyclase; sGCox, oxidized soluble gu
CBF, cerebral blood ﬂow. Solid line, stimulation; broken line inhibition.preparations treated with either fasudil (Rho-kinase inhibitor) or
apocynin (reduced nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase inhibitor) instead dilated in response to ACh
(15). Inhibition of Rho-kinase and NADPH oxidase activities
appear to prevent the cigarette smoke-mediated impairment of
endothelium-dependent vasodilatation. Recently, cigarette smoke
extract (CSE) without nicotine and tar is also known to cause
endothelial dysfunction via increased vascular oxidative stress
(16), and stable carbonyl compounds (acrolein and methyl vinyl
ketone) in the CSE induce protein kinase C-dependent activation
of NADPH oxidase and subsequent generation of reactive oxygen
species via NADPH oxidase (17,18). A functional transcranial
Doppler study demonstrated impaired visually evoked ﬂow ve-
locity response caused by cigarette smoking in otherwise healthy
young subjects (19). The number of cigarettes smoked per day
was negatively correlated with frontal gray matter perfusion
measured at 5 weeks of abstinence from alcohol in alcohol
dependent individuals; improvement of cerebral perfusion by
alcohol abstinence was hindered by cigarette smoking (20).
Kochanowicz et al. (21) obtained evidence suggesting that the
direct effect of smoking one cigarette on the circulation includes
peripheral vasodilatation with possible constriction of the ante-
rior, middle and posterior cerebral arteries in healthy male vol-
unteers. Flow velocity responses evoked by visual stimulation in
the posterior cerebral arteries were worse in smokers and former
smokers than in non-smokers; however, no signiﬁcant difference
was found between former and current smokers (22).
Continued smoking was associated with increased resistance in
uterine, umbilical, and middle cerebral arteries and also led to low
fetal weight at birth (23). Maternal smoking appears to interfere
with placental and fetal circulation via factors eliminating NO
production and augmenting the production of oxygen radicals or
vasoconstrictor substances and results in harmful effects in new-
borns (11).of smoking (S). EM, endothelium; SMC, vascular smooth muscle cell; Nerve, nitrergic
DMA, asymmetric dimethylarginine; BH4, tetrahydrobiopterin; BH2, dihydrobiopterin,
anylyl cyclase; GTP, guanosine triphosphate; cGMP, cyclic guanosine monophosphate;
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Effects of passive maternal smoking on the fetal-placental-
maternal unit were comparable to those with active maternal
smoking as determined by increased resistance in maternal
vasculature and adaptive changes of cerebroplacental circulation
for maintaining fetal cerebral circulation (24). Passive smoking
impaired microvascular function and increased plasma ADMA in
healthy male non-smokers (25). Although the authors did not
determine the inﬂuence on cerebral circulation, increases in
circulating ADMA are expected to impair cerebral circulation via
increased degradation of NO from endothelial cells and nitrergic
nerves.
2.2. Nicotine
Nicotine acts on autonomic ganglia and nerve terminals to
liberate neurotransmitters such as norepinephrine, ACh, NO, and
polypeptides. Nicotine acutely dilates cerebral vasculatures in
humans and experimental animals via the release of NO from
perivascular nitrergic nerves (26). Chronic exposure to nicotine
elicits blunted NO-induced vasodilatation in pial arteries and in-
crease in cortical blood ﬂow (27). Chronic nicotine appears to
induce cerebral hypoperfusion via degradation of NO by increased
oxidative stress, whereas acute and chronic exposure to nicotine
impairs endothelial function through decreased eNOS-derived NO
and decreased NO bioavailability possibly as a result of oxidative
stress (11).
Treatment for 60 min of isolated canine basilar arteries with
nicotine (10e6 M), which is equivalent to the serum level of habitual
smokers, attenuated endothelium-dependent dilatation and NO
synthesis; nicotine also inhibited NO synthesis in cultured vascular
endothelial cells (28). NO synthase-dependent, but not indepen-
dent, pial arteriolar vasodilatation in vivo was impaired and su-
peroxide anion was increased in rats chronically (2 weeks) treated
with nicotine; apocynin alleviated impaired NOS-dependent cere-
bral vasodilatation; chronic exposure to nicotine increased
p47phox protein in the parietal cortex (29). It was suggested that
chronic exposure to nicotine impairs NOS-dependent cere-
broarterial dilatation by a mechanism related to the formation of
superoxide anions.
3. Cigarette smoking and Alzheimer's disease (AD)
Cardiovascular risk factors, including smoking, hypercholester-
olemia, hypertension, alcohol consumption and diabetes mellitus,
aggravate risk for vascular dysfunction that contributes to de-
mentia (30). Vascular risk factors participate in impairments of
endothelial function and increase the risk of incident AD dementia
(31). Midlife hypertension is associated with cognitive decline (32).
Smoking is associated with an increased risk of AD (33,34). History
of smoking, alcohol consumption and increased homocysteic acid
are also involved in cognitive decline or AD (35). The progression of
cognitive deterioration appears to be related to regional cerebral
blood ﬂow affected by the neuropathologic changes of AD (36).
The increased risk for AD and dementia was associated with
exposure to environmental tobacco smoke at home and exposure
duration (37). Exposure to cigarette smoke appears to increase AD
onset and exacerbates its features in transgenic mouse models of
AD (38). Banning smoking in public areas may help to reduce a
worldwide dementia epidemic. A history of cigarette smoking in
the healthy elderly cohort was associated with decreased structural
integrity of multiple brain regions, speciﬁcally affected by incipient
AD (39). Smoking-induced cerebral oxidative stress is suggested to
be a potential mechanism promoting AD pathology (40). Midlifevascular risk factors, including smoking, increase the risk for AD
(34). Patients with AD have sparser and more tortuous retinal
vessels and narrower retinal venules compared with matched in-
dividuals without dementia (41). These authors suggested that
changes in retinal microvasculature may reﬂect similar patho-
physiological processes in cerebral microvasculature in the brain of
AD patients. In Chinese elderly men, the incidence of AD and
vascular dementia was higher in individuals who are currently
smoking compared with those who never smoked; smoking
together with alcohol consumption was related to a higher risk of
AD and vascular dementia, whereas it was not in individuals that
did not smoke and drink alcohol (42).
3.1. Amyloid-b
Nicotine stimulates mRNA expression of amyloid precursor
protein (APP) in the amygdale and hippocampus inmice; treatment
of neuroblastoma cells with nicotine increased the expression of
APP, whereas co-treatment with mecamylamine, a nicotinic re-
ceptor antagonist, attenuates the stimulating effect of nicotine on
APP, suggesting that nicotine facilitates the increase in APP
expression (43). In transgenic mouse models of AD, exposure to
smoking increases the severity of some abnormalities typical of AD,
including amyloidogenesis, neuroinﬂammation, and tau phos-
phorylation (38).
Hypoxia increases Ab deposition and neuritic plaque formation
and potentiates the memory deﬁcit in APP transgenic mice (44).
There is a link between cerebral ischemia/hypoxia and APP pro-
cessing (45). Brain hypoperfusion appears to result in the classic
neurodegenerative regions involving the formation of Ab plaques
and neuroﬁbrillary tangles (5). Cerebral hypoperfusion triggers
early vascular disposition of peripherally applied human Ab 1e-42,
later forming stable Ab deposits in mice (46). Hypoxia rapidly in-
creases hypoxia-inducible factor -1a expression which in turn en-
hances b-site APP cleaving enzyme 1 (BACE1) promoter activity
that causes an increase in Ab generation due to higher APP cleavage
(47). Cerebral hypoperfusion associated with impaired endothelial
function by smoking also participates in the increased production
of Ab. Levels of oxidative stress were increased in the hippocampus
of the group of rats exposed to cigarette smoke; smoking affects
APP processing by increasing the production of secreted APPb and
accumulation of b-amyloid peptide in the hypocampus CA3 and
dentate gyrus region (48). There is evidence suggesting that the
loss of NO in cultured human cerebrovascular endothelium causes
increased expression of APP and BACE1, thereby resulting in
increased secretion of Ab; increased expression of APP and BACE1
as well as increased production of Ab is detected in the cerebral
microvasculature and brain tissue of eNOS-deﬁcient mice (49).
In pressurized segments of rat posterior cerebral arteries and
ring segments of the rat aorta, treatment with Ab decreased ACh-
induced, endothelium-dependent vasodilatation (50). In isolated
rat basilar arteries exposed for 6 h or longer to Ab1e40 or Ab25e35,
ACh-induced endothelium-dependent dilatation was reduced and
basal phosphorylation of eNOS (at Ser1177) appeared reduced,
suggesting that eNOS activity is inhibited by Ab (51). There is evi-
dence that vasoactive Ab disturbs endothelium-dependent factors,
disrupting cerebrovascular regulation (52). Circulating Ab1e40 im-
pairs cerebrovascular function in transgenic mice over-expressing
mutated forms of APP (53).
Cerebral hypoperfusion due to endothelial as well as nitrergic
nerve dysfunction promotes Ab production and Ab inhibits cerebral
vasodilatation and decreases cerebral blood ﬂow mediated via
eNOS and nNOS-derived NO, leading to the vicious cycle of
decreased cerebral blood ﬂow, increased production of Ab and






Fig. 2. Summarized scheme of direct and indirect actions of smoking on NO synthesis, action and degradation, cerebral blood ﬂow, and Ab synthesis/degradation in the patho-
genesis of AD. ACEI: angiotensin converting enzyme inhibitor.
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precede Ab disposition associated with AD, and Ab accumulation
leads to further decreases in cerebral blood ﬂow (54).
4. AD prophylaxis and drug therapy
4.1. Prophylaxisdthe way to increase cerebral blood ﬂow via NO
production
The most important way of preventing AD is to reduce or
eliminate the burden of AD pathology (55) by eliminating or con-
trolling life style factors, such as smoking (56), alcohol intake (57),
sedentary habit (58), obesity (59), and mental stress in daily life
(60) and also pathological conditions of hypertension (61,62), dia-
betes mellitus (63), hyperlipidemia (64) and hyper-
homocysteinaemia (65,66). Cognitive failures and AD once
established owing to non-recommendable life-habits, especially
smoking that impairs cerebral circulation not only to the smokers
themselves but also to the non-smokers in their vicinity are not
reversed by correcting the habits; however, some cardiovascular
drug therapy is expected to slow the progress of AD.
4.1.1. Diet
There is evidence suggesting that higher adherence to the
Mediterranean diet is associated with reduced risk of developing
mild cognitive impairment and with reduced risk of mild cognitive
impairment to AD (67). In a prospective cohort study on older black
and white adults, stronger adherence to the Mediterranean diet
may reduce the rate of cognitive decline among black, but not
white, older adults (68). Higher adherence to a Mediterranean diet
was associated with slower Mini-Mental State Examination
cognitive decline in elderly French individuals (69). The
Mediterranean-type dietary pattern appears to reduce the rate of
cognitive decline in black and white older adults (70). In an elderly
Australian cohort, therewas a signiﬁcant difference in adherence tothe Mediterranean diet between healthy controls and AD subjects
and in adherence between healthy subjects and those with mild
cognitive impairment (71). There is evidence supporting the hy-
pothesis that the Mediterranean diet and Dietary Approach to Stop
Hypertension are associated with slower rates of cognitive decline
in older persons (72).
There is a signiﬁcant increase in verbal memory scores after
caloric restriction, but no signiﬁcant memory changes are observed
in the control group and the group of increased uptake of unsatu-
rated fatty acid (73). High intake of ﬁsh by Japanese living in ﬁshing
villages (74), Alaskan native American (75), and Greenland Eskimos
(76) contributes to low incidence of cardiovascular disease in these
populations. Increased daily intake of ﬁsh improves endothelial
function via increased release of NO in human and animal studies
(77). In participants aged 65e94 years, dietary intake of n-3 poly-
unsaturated fatty acids and weekly consumption of ﬁsh may reduce
the risk of incident AD (78). Fish consumption, but not vegetable,
alcoholic beverage, or dairy product consumption, is associated
with decreased endothelial dysfunction (79). Total energy and an-
imal fat correlated highly with AD prevalence data; diet, obesity,
and smoking are suggested to be major risk factors for AD (80).
After virgin olive oil, rich in the Mediterranean diet, was
administered over two periods of 3 weeks to males with stable
coronary heart disease, plasma oxidized LDL and lipid peroxide
levels were decreased and activities of glutathione peroxidase were
increased (81). In older adults, consumption of 1e6 alcoholic bev-
erages weekly is associated with a lower risk of incident dementia
(82).4.1.2. Physical exercise
Regular exercise may improve endothelial function via
increased blood ﬂow and laminar shear stress that induce eNOS
activation via serine/threonine protein kinase Akt and result in
enhancement of NO release from endothelial cells. However, its
beneﬁt depends on the type and intensity of training performed;
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state and preserves endothelial function (58). Light physical exer-
cise at midlife, such as gardening, walking, regular exercise
involving sports, were associated with reduced odds of dementia
compared to hardly any exercise; ﬁndings were similar for AD alone
(83). Higher midlife ﬁtness levels seem to be associated with lower
hazards of developing dementia later in life (84). Both higher
physical activity and higherMediterranean-type diet adherence are
independently associated with reduced risk of AD (85).
4.2. Drug therapy
4.2.1. Renin-angiotensin system blockers
Midlife hypertension is associated with cognitive decline (32).
Hypertension accelerates the development of AD-related func-
tional alterations through cerebral vasculature impairment and
reduced NO production (62).
Angiotensin (ANG)-induced, endothelium-derived NO-medi-
ated vasodilatation and blood ﬂow increase have been summarized
in our previous review article (86). Dysfunction of ACh-induced,
endothelium-dependent pial vessel dilatation caused by acute,
single smoking in rats was prevented by ANG-II type 1 (AT1)-re-
ceptor blockade by valsartan (87). In patients with a diagnosis of
probable AD, treatment with renin-ANG-system blockers appears
to modulate serum adipocytokines and glucose homeostasis,
potentially allowing cognitive decline in AD patients (88). In elderly
hypertensive patients with AD, treatment with telmisartan
increased cerebral blood ﬂow in the right supra-marginal gyrus,
superior parietal lobule, cuneus, and lingual gyrus and showed
beneﬁcial effects on cognitive deﬁcits, compared with amlodipine
(89). Candesartan and donepezil prevented ANG II-induced mem-
ory impairment, cerebral blood ﬂow reduction, and ACh level
decrease in the cortex and hippocampus, suggesting that ANG II, via
the AT1 receptor, improves special memory function, cerebral blood
ﬂow and brain ACh levels (90). Streptozotocin-induced diabetic
mice exhibited a decline of spatial learning andmemory; treatment
with telmisartan improved memory deﬁcit and reduced Ab42 and
anti-b-amyloid precursor protein of the hippocampus and cortex
without affecting hyperglycaemia and hypoinsulinaemia, suggest-
ing that this AT1 receptor-blocker ameliorates memory deﬁcits in
diabetic mice (91). Treatment of stroke-prone spontaneously hy-
pertensive rats with imidapril, an angiotensin converting enzyme
(ACE) inhibitor, increased the plasma concentrations of NO2/NO3
and augmented cerebral arterial diameter and mean blood ﬂow,
both of which are diminished by treatment with L-NAME, sug-
gesting that imidapril protects cerebral vasculatures in these hy-
pertensive rats by elevating the release of NO (92).
In newborn pigs, the AT2 receptor agonist CGP42112A induced
pial arterial dilatation that was blocked by treatment with L-NA,
suggesting that NO release contributes to AT2 receptor-mediated
vasodilatation (93). Treatment of type 2 diabetes mellitus with a
newly developed AT2 receptor agonist (C21) increased cerebral
blood ﬂow, but an anti-dementia drug memantine did not inﬂu-
ence the ﬂow; treatment with C21 alone or a combination of C21
and memantine increased hippocampal ﬁeld-excitatory post-
synaptic potential; treatment with C21 or memantine increased
ACh level, suggesting a new therapeutic approach against cognitive
decline using C21 and memantine (94). Ca2þ channel blockers, ACE
inhibitors, and AT1 receptor blockers may be beneﬁcial in dimin-
ishing the risk of dementia associated with hypertension (95).
However, there is evidence suggesting that ACE degrades Ab
(96e98). Therefore, lowering ACE levels by ACE inhibitors may have
adverse consequences for patients with AD (Fig. 2). Hypertension
accelerates the development of AD-related functional alterations
through cerebral vasculature impairment and reduced NOproduction in a mouse model of the disease (62). Accumulation of
cellular Ab and tau were decreased with telmisartan (0.3 mg/kg/
day, given orally for 6e18months) in SHR-stroke-resistant rats (99).
4.2.2. Peroxisome proliferator-activated receptor g (PPARg)
agonists
PPARg serves as potential therapeutic targets for treating the
metabolic syndrome and its related risk factors (100,101), mainly
participating in elimination of the synthesis and actions of consti-
tutively induced NO (102). PPARg agonists, such as pioglitazone,
rosiglitazone, and the synthetic agonist GW1929, are used as a
therapeutic agent in neurological disorders, including improve-
ment of memory recognition (103).
The use of rosiglitazonewas associatedwith improved cognition
and memory in patients with mild to modulate AD disease (104).
Clinical trials reported that PPARg agonists improved cognition and
memory in AD patients with data derived from their effects on
peripheral tissues, including cerebral vasculatures, rather than on
the central nervous system (105). In patients with AD accompanied
by type II diabetes mellitus that were treated daily with pioglita-
zone, cognition and regional blood ﬂow in the parietal lobe were
improved, while the control group showed no improvement;
plasma Ab40/Ab42 ratio increased in the control group but showed
no change in the pioglitazone group (106). One-month oral
administration of pioglitazone ameliorated the production of
reactive oxygen species, promoted eNOS phosphorylation, and
increased available NO, resulting in improvement of cerebral arte-
rial relaxation in rats (107). Treatment with pioglitazone restored
in vivo muscle oxidative capacity in diabetic rats (108). Metformin
restored endothelial function through inhibiting oxidative stress
and increasing NO availability on activation of the adenosine
monophosphate-activated protein/PPARg pathway in obese dia-
betic mice (109).
There is evidence suggesting that total area and staining in-
tensity of Ab1e42-positive amyloid deposits in the hippocampus and
cortex of APPV7171 transgenic mice are reduced when animals are
given a 7 day oral treatment with pioglitazone (110). Whether the
decreased Ab deposit is related to NO-mediated increase in cerebral
blood ﬂow is not determined. However, increased amounts of Ab
impair endothelial function (51); therefore, the pioglitazone-
induced decrease in Ab is expected to improve endothelium-
dependent cerebral vasodilatation. In a murine model of AD, pio-
glitazone reduced brain levels of soluble and insoluble Ab levels
and the reduction of amyloid levels was associated with a reversal
of contextual memory deﬁcits (111). In the triple transgenic mouse
model of AD, treatment with pioglitazone improved learning on the
active avoidance task, reduced serum cholesterol, and decreased
hippocampal Ab and tau deposits, suggesting that thiazolidines can
ameliorate cognitive deﬁcits associated with AD-related pathology
(112).
In type 2 diabetic mice, PPARg activation by telmisartan appears
to protect against cognitive decline by preserving the integrity of
the blood brain barrier (113). In transgenic mice expressing a
dominant negative mutation in human PPARg (P467L), dilator re-
sponses to exogenously applied and endogenously produced NO
were impaired in large cerebral arteries in vitro and small cerebral
arterioles in vivo; mechanisms underlying these inhibitory effects
after interferencewith PPARg involved Rho kinase but not oxidative
stress-related mechanisms (114). These authors suggest that ther-
apeutic approaches to target PPARg in cerebral vasculature may be
beneﬁcial in preventing or slowing the progression of vascular
diseases in the brain.
As compared with pioglitazone, GFT1803, a PPAR agonist that
activates PPAR isoforms (a, b and g), in the APP/PS1 mouse model
produced quantitatively superior and qualitatively different
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insoluble Ab content (115).4.2.3. 5-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
(statins)
In anesthetized Zucker obese rats, rosuvastatin improved cere-
brovascular function independently from its lipid-lowering effect by
the inhibition of NAD(P)H oxidase (116). Simvastatin improved
reactivity of cerebral arteries, rescued the blood ﬂow response to
neuronal activation, attenuated oxidative stress and inﬂammation,
and reduced cortical soluble Ab levels and the amount of Ab plaque-
related dystrophic neuritis in APP transgenic mice (117). Simvastatin
fully restored short- and long-termmemory in adult, but not in aged
mice; these beneﬁcial effects occurred without any decreasing effect
of this statin on brain Ab levels or plaque load, suggesting that brain-
penetrant statins bear therapeutic promise in early AD (118).
Treatment with a statin was associated with a signiﬁcantly
lower risk of dementia in a cohort of elderly patients in Taiwan
(119). Statin use was associated with 61% lower AD mortality,
whereas the use of other cholesterol-lowering medications was notFig. 3. Modiﬁcation by sectioning (Denerv) of postganglionic neurons from the pterygopa
(10 Hz) of middle (M) and posterior (P) cerebral, posterior communicating (Pc), and intracra
aspect (rostral side, right) of the pterygopalatine ganglion and neurons to the ganglion (grea
left, before nerve stimulation; top right, during nerve stimulation without nerve sectioning;
stimulation after denervation of positions #1 and #2.
Reproduced with permission from J Cereb Blood Flow Metab 20: 700e708, 2000.(120). On the other hand, analyses from studies on established
dementia from two large randomized controlled trials indicate that
statins have no beneﬁt on the primary outcome measures (121).4.2.4. Acetylcholinesterase (AChE) inhibitors
AChE inhibitors, widely known as effective AD therapeutics,
increase cerebral blood ﬂow in AD patients (122e126). Increasing
cerebral blood ﬂow is an efﬁcient means to supply oxygen and
glucose to brain tissues in AD patients. ACh liberated from cholin-
ergic neurons innervating cerebral arteries, even if any, does not
seem to participate in liberating NO from the endothelium (9),
since ACh applied to monkey and dog cerebral arteries does not
induce relaxations but instead elicits contraction (26).
Electrical stimulation of the basal forebrain increased cortical
cerebral blood ﬂow in anesthetized rats and treatment with heptyl-
physostigmine potentiated the stimulation-induced blood ﬂow
increase, suggesting that this effect may participate in the efﬁcacy
of the AChE inhibitor for treatment of AD (127). Electrical stimu-
lation of the parasympathetic ganglion resulted in cerebral vaso-
dilatation in dogs (128) (Fig. 3) and monkeys (129) and increasedlatine ganglion of vasodilator responses to stimulation of the proximal petrosal nerve
nial internal carotid (IC) arteries of an anesthetized dog. The inset indicates the lateral
ter superﬁcial petrosal nerve) and those out of the ganglion (1 and 2). Recordings: top
middle right, during nerve stimulation after denervation of position #1; during nerve
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derlying muscarinic receptor activation in cerebral vasculatures are
not involved in the vasodilator response (128,129,131). The pre- and
postganglionic nerve stimulation activates parasympathetic,
nitrergic neurons innervating cerebral arteries and arterioles, both
of which liberate NO generated via nNOS activation for cerebral
vasodilatation (128,129). AChE inhibitors appear to potentiate ACh
actions at the site of pterygopalatine ganglia by inhibiting the
degradation of ACh liberated from the pre-synaptic sites. Enhanced
ACh actions result in increasing postganglionic nitrergic nerve
impulses and enhancing the release of NO from nerve terminals (9).
Another site of action of AChE inhibitors would be presynaptic
cholinergic nerve terminals innervating the inferior salivatory nu-
cleus; the increased release of ACh activates the nuclear cells
sending down more impulses through the pterygopalatine gan-
glion to nitrergic neurons.
The cerebral blood ﬂow in the middle and posterior cingulate
cortex increased inmildADpatients after donepezil treatment,which
was the neural substrate of the medial cholinergic pathway; the
baseline cerebral blood ﬂow and its changes after drug treatment
were correlatedwith the behavioral changes inADAssessment Scale-
Cognitive subscale scores (126). Increase in the dosage of donepezil
from5 to 10mg/daywas signiﬁcantlymore effective in improving the
AD Assessment Scale score and cerebral blood ﬂow (132).
4.2.5. Sildenaﬁl
Erectile dysfunction is widely known to result mainly from
dysfunctional nitrergic nerves and also impaired actions of
endothelium-derived NO (133). The phosphodiesterase-5 inhibitor
sildenaﬁl is regarded as an efﬁcient therapeutic against erectile
dysfunction (134,135). Increased incidence of erectile failure is seen
in patients with AD (136). Sildenaﬁl enhances neurogenesis and it
has also a memory enhancing action; therefore, it is suggested that
targeting phosphodiesterase-5 with sildenaﬁl offers novel strate-
gies in the treatment of memory impairment (137). L-Citrulline, an
effective precursor of L-arginine and NO, is a potent hydroxyradical
scavenger; therefore, its supplementation appears to be useful for
treatment of erectile dysfunction and AD (138). Data concerning
the efﬁcacy of sildenaﬁl on cognitive dysfunction and AD are still
insufﬁcient.
4.2.6. Others
Topical application of ACh produced dilatation in rat cerebral
arterioles; however, 1 h after a 1min smoking, the effect of AChwas
reversed to vasoconstriction: pre-treatment with fasudil or apoc-
ynin reversed the vasoconstriction by smoking to vasodilatation,
suggesting that inhibitions of Rho-kinase and NADPH oxidase ac-
tivities appear to prevent the smoking-induced impairment of
endothelium-dependent, NO-mediated vasodilatation (15). In
anesthetized rats, cerebral pial arterioles were dilated by ACh; after
smoking, ACh constricted the arterioles but induced vasodilatation
following pretreatment with varenicline, a selective nicotinic ACh
receptor agonist, suggesting that varenicline appears to prevent the
smoking-induced impairment of endothelium-dependent vasodi-
latation (139).
5. Summary
This review article summarizes clinical and experimental ob-
servations supporting that cigarette smoking-induced impair-
ment of cerebral vasodilatation and blood ﬂow is one of the risk
factors for spatial memory disturbance and AD in humans and
experimental animals. Cerebral vascular dysfunction and hypo-
perfusion in the brain are quite important clinical features in AD
patients. Acute and chronic smoking as well as passive smokingimpairs cerebral blood ﬂow due to decreased syntheses and ac-
tions of NO liberated from endothelial cells and nitrergic nerves
and to augmented oxidative stress. This is also true when nicotine
is administered, except for acute application of nicotine, which
stimulates nitrergic nerves and liberates NO. Cerebral hypo-
perfusion due to decreased actions of NO by smoking would
participate in impaired cognitive function and AD. Cerebral blood
ﬂow decrease promotes the production of Ab and Ab impairs the
NO production; removal of the smoking habit is expected to be
effective in interfering with this vicious cycle. There are many
ways to prevent AD by maintaining good quality health habits in
daily life from young age (moderate exercise, adequate food
intake, no smoking, limited alcohol drinking and reduced stress)
and also by early extensive treatment of hypertension, diabetes
mellitus, hypercholesterolemia. Recent advances in research on
cardiovascular disease and diabetes therapeutics, such as AT1
receptor antagonists and PPARg agonists, have been proven to be
effective in treating cognitive failure and AD. Further develop-
ment of research on potent and safe therapeutics should be
encouraged. In addition, prophylaxis from a young age by con-
trolling daily life-habits, especially quit smoking, would also be
important. Social and governmental efforts as well as doctor's
advice to patients are required to increase success in preventing
onset and progress of AD.
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